20.36

2.16% 0.43

Moonlake Immunotherapeutics (MLTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MLTX Giù? Forum Previsione

Precedente Chiudi:

$19.93

Aprire:

$19.96

Volume 24 ore:

1.94M

Relative Volume:

1.79

Capitalizzazione di mercato:

$1.70B

Reddito:

Utile/perdita netta:

$-230.32M

Rapporto P/E:

-5.7744

EPS:

-3.5259

Flusso di cassa netto:

$-196.04M

1 W Prestazione:

+7.44%

1M Prestazione:

+16.41%

6M Prestazione:

+10.11%

1 anno Prestazione:

-58.35%

Intervallo 1D:

$19.70

$21.28

Intervallo di 1 settimana:

$18.46

$21.28

Portata 52W:

$5.95

$62.75

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Nome

Moonlake Immunotherapeutics

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

41 41 510 8022

Indirizzo

DORFSTRASSE 29, ZUG

Dipendente

130

Cinguettio

Prossima data di guadagno

2026-08-04

Ultimi documenti SEC

MLTX's Discussions on Twitter

Compare MLTX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MLTX Moonlake Immunotherapeutics	20.36	1.70B	0	-230.32M	-196.04M	-3.5259
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-23	Aggiornamento	Wolfe Research	Underperform → Outperform
2026-03-19	Aggiornamento	Rothschild & Co Redburn	Neutral → Buy
2026-01-15	Downgrade	Goldman	Neutral → Sell
2026-01-09	Aggiornamento	BTIG Research	Neutral → Buy
2025-11-03	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-10-02	Downgrade	H.C. Wainwright	Buy → Neutral
2025-10-01	Downgrade	Goldman	Buy → Neutral
2025-09-30	Downgrade	Citigroup	Buy → Neutral
2025-09-30	Downgrade	Wolfe Research	Outperform → Underperform
2025-09-29	Downgrade	BTIG Research	Buy → Neutral
2025-09-29	Downgrade	Jefferies	Buy → Hold
2025-09-29	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-09-29	Downgrade	Stifel	Buy → Hold
2025-07-28	Iniziato	Rothschild & Co Redburn	Neutral
2025-05-19	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2025-03-18	Iniziato	RBC Capital Mkts	Outperform
2025-01-17	Aggiornamento	Goldman	Neutral → Buy
2024-11-05	Ripresa	Wedbush	Outperform
2024-08-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2024-06-25	Iniziato	Oppenheimer	Outperform
2024-04-02	Iniziato	Goldman	Neutral
2024-02-15	Iniziato	Wolfe Research	Outperform
2023-12-08	Iniziato	Citigroup	Buy
2023-11-02	Iniziato	Stifel	Buy
2023-09-14	Downgrade	Bryan Garnier	Buy → Neutral
2023-08-31	Iniziato	Needham	Buy
2023-06-15	Iniziato	Barclays	Equal Weight
2023-05-01	Iniziato	Guggenheim	Buy
2023-03-22	Iniziato	Wedbush	Outperform
2023-03-09	Iniziato	BTIG Research	Buy
2023-02-14	Iniziato	Cantor Fitzgerald	Overweight
2023-02-02	Iniziato	Bryan Garnier	Buy
2022-11-11	Iniziato	Jefferies	Buy
2022-08-25	Iniziato	SVB Leerink	Outperform
2022-07-21	Iniziato	H.C. Wainwright	Buy
2022-07-07	Iniziato	Cowen	Outperform

Mostra tutto

Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie

Jul 10, 2026

MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits

Jul 10, 2026

Jul 09, 2026

MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits

Jul 09, 2026

Jul 08, 2026

Behavioral Patterns of MLTX and Institutional Flows - Stock Traders Daily

Jul 08, 2026

Jul 04, 2026

What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI

Jul 04, 2026

MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits

Jul 04, 2026

Jul 03, 2026

MoonLake Immunotherapeutics' CFO Sells 39K Shares - The Motley Fool

Jul 03, 2026

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits

Jul 03, 2026

Jul 02, 2026

Insider Sell: Santos da Silva Jorge Sells 47,775 Shares of MoonL - GuruFocus

Jul 02, 2026

CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX) sells shares under plan - Stock Titan

Jul 02, 2026

Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (M - The National Law Review

Jul 02, 2026

Jul 01, 2026

MoonLake Reports Positive 52-Week Phase 3 Data for Sonelokimab in Hidradenitis Suppurativa - Dermatology Times

Jul 01, 2026

Top biotech stocks to watch in second half of 2026, says Clear Street - Investing.com South Africa

Jul 01, 2026

MLTX Maintained by Leerink Partners -- Price Target Raised to $2 - GuruFocus

Jul 01, 2026

Leerink raises Moonlake stock price target on HS drug data By Investing.com - Investing.com South Africa

Jul 01, 2026

Leerink raises Moonlake stock price target on HS drug data - Investing.com

Jul 01, 2026

Jun 30, 2026

Form 144 MoonLake Immunotherapeutics For: 30 June By Investing.com - Investing.com South Africa

Jun 30, 2026

MLTX (Nasdaq) Rule 144 notice shows 150,000 Class A shares sale (04/10/2026) - Stock Titan

Jun 30, 2026